A recent study suggests that commonly prescribed diabetes medications, like metformin, might diminish some of the key advantages gained from exercise.
Researchers at Rutgers University discovered that adults taking metformin while exercising exhibited only minor enhancements in blood sugar levels, blood vessel health, and overall fitness. This was particularly noticeable when compared to those who exercised without the medication.
The research, detailed in The Journal of Clinical Endocrinology & Metabolism last month, reinforces the notion that both metformin and physical activity are beneficial for managing blood sugar and heart health. However, their combined effects may lessen the benefits typically associated with exercise.
Lead author Stephen Mullin, a professor at Rutgers, pointed out, “Metformin is the most commonly used drug for managing blood sugar globally.” He also indicated a lack of clarity on the best approach regarding simultaneous treatment with both the drug and exercise. If taking both doesn’t yield optimum results, individuals might experience decreased energy or a lack of health improvement, leading to a sense of discouragement that can impact overall well-being.
According to the CDC, approximately 35 million Americans live with type 2 diabetes, and countless others worldwide rely on metformin not only for blood sugar control but also for experimental anti-aging effects.
The 16-week study involved 72 adults at risk for metabolic syndrome—a cluster of conditions that includes high blood sugar and blood pressure, which heightens the potential for diabetes and heart disease. Participants were categorized into four groups: two engaged in high- or low-intensity workouts using a placebo, while the other two followed a similar exercise regimen with a daily dosage of 2,000 milligrams of metformin.
Results indicated that those who exercised without medication showed a significant increase in vascular insulin sensitivity, enhancing the capacity of blood vessels to respond to insulin for better nutrient delivery to muscles. Conversely, that response appeared to diminish when metformin was introduced. In this group, inflammation levels were also lower, and fasting blood sugar readings showed improvements.
The exact reasons remain uncertain, but researchers suspect that metformin might interfere with cellular adaptability in response to exercise.
Marin expressed that this may relate to heart health. He stated, “Enhancing vascular function is crucial for delivering nutrients, like sugar, to tissues. If sugar isn’t reaching those tissues, it might explain the reduced capability of muscles to respond to insulin and utilize sugar for energy.”
The researchers acknowledged the limited scope of their study and its focus on adults at risk for metabolic syndrome, cautioning that results may not extend to everyone with diabetes.
They emphasized that individuals should not discontinue either metformin or their exercise regimen but rather consult with healthcare providers to determine the best approaches for combining treatment and activity.
Pursuing further research, the team plans to investigate if metformin interacts differently with strength or resistance training, as well as whether modifying the dose or timing could mitigate its influence.
Dr. Cutler, a family medicine physician, noted that while the findings might seem disheartening, it’s crucial to understand them within a broader context. He highlighted that the minor drop in vascular insulin sensitivity should be balanced against the significant benefit of blood sugar reduction that metformin offers, which lowers the risk of diabetes-related complications.
He further suggests that while the results shouldn’t alter the prescription for diabetes patients dependent on metformin, they could be relevant for those using it for other motivations, such as anti-aging or cancer prevention.
In summary, metformin remains a primary treatment for type 2 diabetes.
